250 applies to orders below Rs
Sodium-glucose transporters (SGLT)-inhibitors The treatment of T2DM with glyflozines, sodium-glucose co-transporter 2 inhibitors, represents a new therapeutic approach ( Among SGLT2 inhibitors, three of them have been approved by the FDA and EMA: canagliflozin (2013), dapagliflozin (2014) and empagliflozin (2014)
Tracking infant weight gain and development closely
Molecules 19 (12), 2009120112 (2014)
Currently, designing and producing personalized peptide vaccines is a time-consuming and costly process, but with new sequencing technologies, bioinformatics, and techniques for predicting T-cell epitopes, this may become a highly valuable tool in the future